South Africa is a study in contrasts. And the 2026 public health agenda is no exception. Breakthrough HIV prevention medicine ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing ...

After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the ...

A possible approval of orforglipron, initial revenue from the drug, and ongoing revenue from the rest of the weight loss portfolio should generate significant growth. And that's why I predict that ...

Pharmaceutical companies have raised prices on hundreds of drugs so far this month despite federal efforts to rein in drug ...

Mason Newman was prescribed Mounjaro, a drug used in treating diabetes, which also suppresses appetite and can be combined ...

Here's what San Antonio doctors say about the widespread use of GLP-1 medications for obesity, diabetes and other conditions.

Shares of pharmaceutical giant Eli Lilly & Co. declined sharply following an unexpected regulatory update from the U.S. Food ...

Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...

A study previously carried out by Eli Lilly, the manufacturers of popular weight loss drug Mounjaro, found that of the 308 ...

Strive Specialities Inc., a major provider of compounded medicines, filed a federal lawsuit against pharmaceutical giants Eli ...